CN110088098A - 喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途 - Google Patents

喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途 Download PDF

Info

Publication number
CN110088098A
CN110088098A CN201680080100.7A CN201680080100A CN110088098A CN 110088098 A CN110088098 A CN 110088098A CN 201680080100 A CN201680080100 A CN 201680080100A CN 110088098 A CN110088098 A CN 110088098A
Authority
CN
China
Prior art keywords
substituted
cyclopropyl
methyl
ethyl
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680080100.7A
Other languages
English (en)
Other versions
CN110088098B (zh
Inventor
徐柏玲
陈晓光
姚海平
季鸣
金晶
周洁
王珂
赵大龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Collab Pharma Co ltd
Institute of Materia Medica of CAMS
Original Assignee
Beijing Collab Pharma Co ltd
Institute of Materia Medica of CAMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Collab Pharma Co ltd, Institute of Materia Medica of CAMS filed Critical Beijing Collab Pharma Co ltd
Publication of CN110088098A publication Critical patent/CN110088098A/zh
Application granted granted Critical
Publication of CN110088098B publication Critical patent/CN110088098B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

本发明公开了一类新的喹唑啉‑2,4(1H,3H)‑二酮类PARP‑1抑制剂、及其制法和药物组合物与用途。具体而言，本发明涉及通式I所示的喹唑啉‑2,4(1H,3H)‑二酮类衍生物及其立体异构体、其可药用盐，及其制备方法，含有一个或多个该类化合物的组合物，和该类化合物在制备、预防和/或治疗肿瘤药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN201680080100.7A 2016-01-26 2016-01-26 喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途 Active CN110088098B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/072135 WO2017128036A1 (zh) 2016-01-26 2016-01-26 喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途

Publications (2)

Publication Number Publication Date
CN110088098A true CN110088098A (zh) 2019-08-02
CN110088098B CN110088098B (zh) 2022-04-15

Family

ID=59397019

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680080100.7A Active CN110088098B (zh) 2016-01-26 2016-01-26 喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途

Country Status (2)

Country Link
CN (1) CN110088098B (zh)
WO (1) WO2017128036A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114929704A (zh) * 2019-12-27 2022-08-19 微境生物医药科技(上海)有限公司 含螺环的喹唑啉化合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113929674B (zh) * 2021-11-22 2023-09-22 中国药科大学 含1,4-二氢喹唑啉结构的化合物及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102731416A (zh) * 2011-04-01 2012-10-17 南京英派药业有限公司 1-(芳基甲基)-喹唑啉-2，4-二酮作为parp抑制剂及其应用
CN103443085A (zh) * 2011-03-14 2013-12-11 永恒生物科技公司 喹唑啉二酮及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105461697A (zh) * 2014-04-29 2016-04-06 中国医学科学院药物研究所 喹唑啉酮类parp-1抑制剂及含有它们的组合物和抗肿瘤用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103443085A (zh) * 2011-03-14 2013-12-11 永恒生物科技公司 喹唑啉二酮及其应用
CN102731416A (zh) * 2011-04-01 2012-10-17 南京英派药业有限公司 1-(芳基甲基)-喹唑啉-2，4-二酮作为parp抑制剂及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114929704A (zh) * 2019-12-27 2022-08-19 微境生物医药科技(上海)有限公司 含螺环的喹唑啉化合物

Also Published As

Publication number Publication date
CN110088098B (zh) 2022-04-15
WO2017128036A1 (zh) 2017-08-03

Similar Documents

Publication Publication Date Title
CN110256421A (zh) Kras-g12c抑制剂
CN108440515B (zh) 取代的苯并呋喃基和苯并噁唑基化合物及其用途
CA2661166C (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
WO2021027911A1 (zh) 新型螺环类K-Ras G12C抑制剂
CN111440189B (zh) 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用
CN105461697A (zh) 喹唑啉酮类parp-1抑制剂及含有它们的组合物和抗肿瘤用途
CN106413402A (zh) 乙型肝炎核心蛋白变构调节剂
CN102485721A (zh) 取代的2,3-二氮杂萘酮化合物及其用途
CN102827073A (zh) 治疗活性组合物和它们的使用方法
CN101925595A (zh) 酞嗪酮衍生物
BR112015004205B1 (pt) Sulfamoil-arilamidas, seu uso das mesmas como medicamentos para o tratamento da hepatite b, composição farmacêutica que as compreende e produto
CN106715440A (zh) 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
CN102510863B (zh) 吡唑衍生物
CN103459382B (zh) 用于抑制pask的杂环化合物
CN107151250B (zh) 嘧啶类七元环化合物、其制备方法、药用组合物及其应用
CN112661745A (zh) 用作cdk7激酶抑制剂的化合物及其应用
CN102325754A (zh) 含杂原子的环状化合物
WO2012031563A1 (zh) 杂环氨基小檗胺衍生物、其制备方法和应用
TW201710250A (zh) 經取代之喹喏啉衍生物
TWI815887B (zh) 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
CN110088098B (zh) 喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途
WO2006082821A1 (ja) ヘルペスウイルスが関与する疾患の予防若しくは治療剤
KR20210039417A (ko) 치환된 테트라하이드로사이클로펜타[c]피롤, 치환된 디하이드로피롤리진, 이의 유사체, 및 이의 사용 방법
CN110903310B (zh) 一种硼酸酯类药物及其用途
CN109111439B (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant